SGLT2 Inhibitor and GLP-1 Receptor Agonist Combination Therapy Substantially Improved the Renal Function in a Patient with Type 2 Diabetes: Implications for Additive Renoprotective Effects of the Two Drug Classes
-
- Nonomura Kenta
- Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Japan
-
- Iizuka Katsumi
- Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Japan Center for Nutritional Support and Infection Control, Gifu University Hospital, Japan
-
- Kuwabara-Ohmura Yayoi
- Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Japan
-
- Yabe Daisuke
- Department of Diabetes and Endocrinology, Graduate School of Medicine, Gifu University, Japan
抄録
<p>A 72-year-old man had type 2 diabetes (T2D) that had been diagnosed at 54 years old. Macroalbuminuria was first detected at age 64. While his HbA1c had been kept below 7%, his estimated glomerular filtration rate (eGFR) was declining rapidly. At 70 years old, his eGFR dropped below 50 mL/min/1.73 m2. A renal biopsy revealed diabetic nephropathy. Sodium glucose transporter 2 inhibitors (SGLT2i)/glucagon-like peptide-1 receptor agonists (GLP-1RA) combination therapy substantially improved his eGFR and urinary albumin level, and the renoprotective effect persisted for the two-year study period. These findings suggest that SGLT2i and GLP-1RA can additively improve the renal function in patients with T2D. </p>
収録刊行物
-
- Internal Medicine
-
Internal Medicine 59 (12), 1535-1539, 2020-06-15
一般社団法人 日本内科学会